OTLK · Outlook Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on OTLK. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About OTLK · Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Live Quote
HOLD (score +0) · 12-1 mom -81.2% · RSI 77.3 · above_both · -42.8% from high
Targets blend Wall Street consensus (3 analysts: low $0.50 / mean $5.50 / high $10.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.
Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.
OTLK has triggered on an insider cluster (4 directors buying open-market shares over May 26-27 at $0.40-$0.44, totaling ~$243K) coinciding with a major positive catalyst — the FDA granted its Formal Dispute Resolution appeal on May 26, concluding substantial evidence of effectiveness exists for LYTENAVA (bevacizumab-vikg) in neovascular AMD and directing staff to finalize labeling. The company plans a Class 1 BLA resubmission by June 2026 with an accelerated review timeline. However, the stock has already surged ~170% from its March low ($0.198) to $0.536 on this news, creating significant timing risk for new entry. Underlying fundamentals remain extremely distressed — pre-revenue, -$633M accumulated deficit, going-concern qualified financials, only $7.7M cash against near-term debt maturities of ~$27M, and massive ongoing dilution (shares outstanding doubled in 6 months to 105M). No 13F or politician trade data available. Options IV is extremely elevated (~160-215%), making premium collection strategies attractive for those who want exposure without directional risk at these levels.